Menu
Not yet recruiting NCT06747936

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

Phase III Interventional Primary Hypercholesterolemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AD-2281, AD-2282, Placebo of AD-2282.
Who it may be relevant to
Registry conditions: Primary Hypercholesterolemia. Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients with Primary Hypercholesterolemia.

Overview

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

Interventions

  • Drug AD-2281
    PO, Once daily, 8weeks
  • Drug AD-2282
    PO, Once daily, 8weeks
  • Drug Placebo of AD-2282
    PO, Once daily, 8weeks

Primary outcome measures

  • Change rate of LDL-C [Time frame: from baseline at 8 weeks]

Eligibility criteria

Inclusion criteria

  • Signed informed consent
  • Patients with Primary Hypercholesterolemia
  • Other inclusions applied

Exclusion criteria

  • Patients with Secondary Hypercholesterolemia
  • Other exclusions applied

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06747936 · AD-228P3

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗